Patents by Inventor Jatin M. Patel
Jatin M. Patel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170333353Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: ApplicationFiled: March 6, 2017Publication date: November 23, 2017Inventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Patent number: 9616028Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: GrantFiled: May 7, 2015Date of Patent: April 11, 2017Assignees: AstraZeneca AB, AstraZeneca UK LimitedInventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Patent number: 9198925Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.Type: GrantFiled: May 2, 2014Date of Patent: December 1, 2015Assignee: AstraZeneca ABInventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
-
Publication number: 20150238421Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: ApplicationFiled: May 7, 2015Publication date: August 27, 2015Inventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Patent number: 9050258Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: GrantFiled: August 13, 2013Date of Patent: June 9, 2015Assignee: AstraZeneca ABInventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Publication number: 20140335170Abstract: The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets, granulations, and capsules.Type: ApplicationFiled: May 6, 2014Publication date: November 13, 2014Applicant: Bristol-Myers Squibb CompanyInventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Peter Timmins
-
Publication number: 20140243262Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.Type: ApplicationFiled: May 2, 2014Publication date: August 28, 2014Applicant: ASTRAZENECA ABInventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
-
Patent number: 8716251Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.Type: GrantFiled: January 4, 2013Date of Patent: May 6, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
-
Publication number: 20130330406Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: ApplicationFiled: August 13, 2013Publication date: December 12, 2013Applicants: AstraZeneca UK Limited, Bristol-Myers Squibb CompanyInventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Patent number: 8535715Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: GrantFiled: November 12, 2010Date of Patent: September 17, 2013Assignees: Bristol-Myers Squibb Company, AstraZeneca UK LimitedInventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Patent number: 8361972Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.Type: GrantFiled: June 21, 2012Date of Patent: January 29, 2013Assignee: Bristol Myers-Squibb CompanyInventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
-
Publication number: 20120294936Abstract: The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets, granulations, and capsules.Type: ApplicationFiled: November 12, 2010Publication date: November 22, 2012Applicants: ASTRAZENECA UK LIMITED, BRISTOL-MYERS SQUIBB COMPANYInventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Peter Timmins
-
Publication number: 20120282336Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: ApplicationFiled: November 12, 2010Publication date: November 8, 2012Applicants: ASTRAZENECA UK LIMITED, BRISTOL-MYERS SQUIBB COMPANYInventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Publication number: 20120263786Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.Type: ApplicationFiled: June 21, 2012Publication date: October 18, 2012Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
-
Patent number: 8221786Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.Type: GrantFiled: November 18, 2010Date of Patent: July 17, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
-
Publication number: 20110064801Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.Type: ApplicationFiled: November 18, 2010Publication date: March 17, 2011Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
-
Patent number: 7851502Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.Type: GrantFiled: March 21, 2008Date of Patent: December 14, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
-
Publication number: 20080234366Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.Type: ApplicationFiled: March 21, 2008Publication date: September 25, 2008Applicant: Bristol-Myers SquibbInventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
-
Publication number: 20040005358Abstract: A modified-release vasopeptidase inhibitor formulation is provided which is capable of releasing vasopeptidase inhibitor, preferably omapatrilat or gemopatrilat, in a manner to provide therapeutically effective NEP inhibitory activity and therapeutically effective ACE inhibitory activity, in a balanced manner, for a predetermined duration to lower blood pressure and/or treat heart failure. In a preferred formulation, the NEP inhibitory activity and ACE inhibitory activity have balanced release characteristics.Type: ApplicationFiled: April 21, 2003Publication date: January 8, 2004Inventors: Peter H. Slugg, Nemichand B. Jain, Rajesh Krishna, Robert L. Jerzewski, Ronald L. Smith, Jatin M. Patel, Bimal K. Malhotra
-
Patent number: 6034085Abstract: The crystalline, stable methanesulfonate salt of nefazodone showed significantly higher intrinsic dissolution in water and THAM buffer (pH 7.5) compared to other salts of nefazodone. The faster dissolution rate of this salt at neutral pH suggests better dissolution and absorption in the intestine, allowing controlled release of nefazodone for oral formulations.Type: GrantFiled: September 29, 1998Date of Patent: March 7, 2000Assignee: Bristol-Myers Squibb Co.Inventors: Hemant N. Joshi, Terry D. Wilson, Jatin M. Patel
